Diagnostics Digest CM Life Science

In this season opener, we sit down with Krista Ewing, Senior Global Product Manager at Porex Corporation. As a renowned global leader in advanced porous solutions across various industries, including medical devices and writing instruments, it provides high-value solutions for product design challenges related to absorption, diffusion, filtration, and more.
Nathan chats with Krista about the journey behind the development of TruFlow, the infamous lateral flow product that emerged in response to the challenges faced during the COVID-19 pandemic. The conversation highlights the critical issues of inconsistency in glass fibre materials used for these tests, exacerbated by the soaring demand for COVID-19 diagnostics. Truflow was conceived as a solution to these challenges, aiming to provide more dependable and uniform materials for lateral flow tests, ultimately enhancing the accuracy and reliability of these crucial diagnostics.
Press play to learn about the journey and significance of TruFlow in revolutionising lateral flow testing and the impressive teamwork driving its success.

Hosted on Acast. See acast.com/privacy for more information.

This is the final episode of our 3-part series with the exciting POC diagnostics start-up, ProtonDx.
ProtonDx is founded on a decade of research and development at Imperial College London. Its vision is to develop ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need. In 2022, the business received a CE mark for its cutting-edge Dragonfly product. Now the ProtonDx team are looking to commercialise this essential testing kit.
In this episode, CM Life Science Business Manager, Nathan Sharpe, speaks to the Co-Founder and Chief Technology Officer of ProtonDx, Dr. Nicolas Moser. Nicolas earned an MSc at Imperial College London with distinction and received the Hertha Ayrton Centenary Prize (best MSc project) and the MSc Analogue and Digital Integrated Circuit Design Outstanding Achievement Prize (highest ranking MSc student).
In this episode, we cover the future of diagnostics from the perspective of an award-winning scientist and industry innovator. If you would like to learn more about the new possibilities with lab-on-chip, then be sure to give it a listen.

Hosted on Acast. See acast.com/privacy for more information.

In this next episode of our 3-part series with the exciting POC diagnostics start-up, Nathan sits down with Bob Enk, Chairman & President, and Dr. Jesus Rodriguez Manzano, Chief Scientific Officer for an exclusive chat about the future of diagnostics with ProtonDx.
Dr. Rodriguez Manzano has a strong interdisciplinary background in microbiology, molecular biology and bioengineering, and his research interest includes single-molecule technologies, machine learning applied to healthcare, and clinical diagnostics, with a particular interest in low- and middle-income countries. He is the author of over 90 scientific publications and 14 international patent applications and helped co-found ProtonDx just over 3 years' ago.
Bob Enk is Chairman and President at ProtonDx. An experienced investing pioneer and CEO with an alternative mindset and demonstrated history of innovation and growth across financial services and healthcare. After joining the business nearly 2 years ago to take it to the next level in its stratospheric growth, he offers insight into his industry experience interacting with key players and clients, working with strategic partners and major investors, and loads more.
From the stimulus for this impressive brand to the reality of using point-of-care to tackle infectious disease in 2023 and beyond. Listen to learn more about new possibilities with lab-on-chip,
the vision for developing ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need, and the plan to commercialise this essential testing kit.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, we begin our 3-part series with the exciting POC diagnostics start-up, ProtonDx.
ProtonDx is founded on a decade of research and development at Imperial College London. Its vision is to develop ultra‑rapid, extremely precise, molecular testing for everyone at the point‑of‑need. In 2022, the business received a CE mark for its cutting-edge Dragonfly product. Now the ProtonDx team are looking to commercialise this essential testing kit.
Our conversations started with the co-founder and CEO, Professor Pantelis Georgiou. Pantelis holds the position of Professor of Biomedical Electronics at Imperial College London. He heads the Bio‑inspired Metabolic and Infection Technology Laboratory in the Centre for Bio‑Inspired Technology; a multi‑disciplinary group that invents, develops and demonstrates advanced micro‑devices to meet global challenges in biomedical science and healthcare. His research includes applications of lab‑on‑chip technology for genomics and diagnostics targeted towards infectious disease and cancer.
In this episode, CM Life Science Business Manager, Nathan Sharpe, asks Pantelis about the mission that ProtonDx is on: getting molecular testing to the point-of-need. If you are interested in learning more about this ambitious start-up, then be sure to have a listen.

 

Hosted on Acast. See acast.com/privacy for more information.

In this episode of Diagnostics Digest, CM Life Science Business Manager Nathan Sharpe speaks with Kevin Fallon, CEO & Co-Founder of FlexMedical Solutions.
Since 2016 FlexMedical has been on an exciting journey, jumping from strength to strength. From significant headcount growth to major investment in both equipment and facilities, the business has become one of the most trusted IVD manufacturers in the world in its short lifespan. Now, they're ready to make the next big move.
Our team went to visit FlexMedical at their Scottish HQ, where Nathan caught up with Kevin to discuss the company's exciting plans as one of the world's go-to IVD manufacturers. Find out behind the scenes from the journey to the top, the impact of significant growth, and loads more in this fascinating chat.
If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please get in touch at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, CM Life Science Business Manager, Nathan Rigby, speaks with Erez Naaman, Co-Founder & CTO at Scopio Labs.
Prior to Scopio Labs, Erez was VP of Engineering & Business Development at OrCam, a leading Israeli high-tech start-up. He brings much of his insight from this experience to this discussion, as well as insight into the development of his current business, trends in AI and how he believes this affects the future of healthcare.
Scopio Labs uses full-field digital cell morphology to automate the analysis of tens of thousands of cells at a time – far more than any human can quantify, bringing dramatically earlier detection and diagnosis of cancers, infections, and other diseases. This technology expedites patients’ access to better care and life-saving treatments, with a key focus on digitizing microscopy and bringing it to the modern age. By providing access to rapid diagnostic tools for the first time. This system includes uniquely built-in computational power to enable AI at the user's fingertips - saving time, enabling collaboration, improving data safety and reducing the need for expensive hardware.
If you're interested in hearing more about Erez and his company, or are fascinated by what AI brings to the future of the space, then be sure to have a listen.
To find out more about Nathan and his work in the diagnostic space, get in touch at nathan.rigby@lifesci-cm.com or connect on LinkedIn to chat.

Hosted on Acast. See acast.com/privacy for more information.